NUVA's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 442.53 -- higher than 92.38% of US-listed equities with positive expected earnings growth.
With a year-over-year growth in debt of 117.73%, Nuvasive Inc's debt growth rate surpasses 88.9% of about US stocks.
Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for NUVA comes in at -39.21% -- higher than that of merely 11.53% of stocks in our set.
Stocks with similar financial metrics, market capitalization, and price volatility to Nuvasive Inc are IART, HRC, CW, JCOM, and HUN.
NUVA's SEC filings can be seen here. And to visit Nuvasive Inc's official web site, go to www.nuvasive.com.
NuVasive develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its products focus on applications for spine fusion surgery. The company was founded in 1997 and is based in San Diego, California.
NUVA Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for NUVA, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Nuvasive Inc ranked in the 15th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 81.5%. In terms of the factors that were most noteworthy in this DCF analysis for NUVA, they are:
The compound growth rate in the free cash flow of Nuvasive Inc over the past 5.44 years is 0.02%; that's higher than only 23.85% of free cash flow generating stocks in the Healthcare sector.
Nuvasive Inc's weighted average cost of capital (WACC) is 10%; for context, that number is higher than 69.4% of tickers in our DCF set.
Nuvasive Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than just 0% of US stocks with positive free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
BHC, MYGN, BSX, EHC, and IDXX can be thought of as valuation peers to NUVA, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Global Minimally Invasive Spinal Implant Market has been brewing up and influencing the international economy with respect to revenue, growth rate, sale, market share, and size. The Global Minimally Invasive Spinal Implant Market research report provides a rational explanation to
SAN DIEGO, Sept. 9, 2020 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the limited availability of the new Precice® Plate for use…
DUBLIN--(BUSINESS WIRE)--The "Spinal Fusion (Orthopedic Devices) - Global Market Analysis and Forecast Model (COVID-19 market impact)" report has been added to ResearchAndMarkets.com's offering. This market model discusses in detail the impact of COVID-19 on Spinal Fusion market for the year 2020 and beyond. Companies Mentioned Medtronic plc NuVasive Inc. DePuy Synthes Inc. Globus Medical Inc. Stryker Corp. Zimmer Biomet Holdings Inc. Lumbar fusions are the most common spinal fusion procedures